Atwood & Palmer Inc. reduced its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 107,089 shares of the medical research company’s stock after selling 1,050 shares during the period. Thermo Fisher Scientific makes up about 4.2% of Atwood & Palmer Inc.’s portfolio, making the stock its 4th biggest holding. Atwood & Palmer Inc.’s holdings in Thermo Fisher Scientific were worth $29,312,000 at the end of the most recent reporting period.
A number of other large investors have also recently added to or reduced their stakes in TMO. Oregon Public Employees Retirement Fund lifted its holdings in Thermo Fisher Scientific by 44,296.5% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 19,565,960 shares of the medical research company’s stock worth $87,000 after purchasing an additional 19,521,889 shares during the last quarter. Norges Bank acquired a new stake in Thermo Fisher Scientific during the 4th quarter worth approximately $946,280,000. FMR LLC lifted its holdings in Thermo Fisher Scientific by 33.4% during the 4th quarter. FMR LLC now owns 8,671,713 shares of the medical research company’s stock worth $1,940,642,000 after purchasing an additional 2,172,574 shares during the last quarter. BlackRock Inc. lifted its holdings in Thermo Fisher Scientific by 3.7% during the 4th quarter. BlackRock Inc. now owns 26,177,278 shares of the medical research company’s stock worth $5,858,214,000 after purchasing an additional 944,035 shares during the last quarter. Finally, Federated Investors Inc. PA lifted its holdings in Thermo Fisher Scientific by 8,025.0% during the 3rd quarter. Federated Investors Inc. PA now owns 560,949 shares of the medical research company’s stock worth $136,916,000 after purchasing an additional 554,045 shares during the last quarter. 88.67% of the stock is owned by institutional investors and hedge funds.
Shares of NYSE TMO opened at $269.55 on Friday. The firm has a market capitalization of $105.31 billion, a price-to-earnings ratio of 24.24, a P/E/G ratio of 1.74 and a beta of 1.13. The company has a quick ratio of 1.24, a current ratio of 1.73 and a debt-to-equity ratio of 0.64. Thermo Fisher Scientific Inc. has a fifty-two week low of $202.83 and a fifty-two week high of $282.98.
The firm also recently declared a quarterly dividend, which was paid on Tuesday, April 16th. Stockholders of record on Friday, March 15th were issued a dividend of $0.19 per share. The ex-dividend date was Thursday, March 14th. This represents a $0.76 dividend on an annualized basis and a dividend yield of 0.28%. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.17. Thermo Fisher Scientific’s payout ratio is 6.83%.
In other news, CFO Stephen Williamson sold 2,500 shares of the business’s stock in a transaction on Monday, March 4th. The stock was sold at an average price of $266.00, for a total transaction of $665,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Gregory J. Herrema sold 3,299 shares of the business’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $263.05, for a total value of $867,801.95. The disclosure for this sale can be found here. Insiders have sold a total of 36,927 shares of company stock valued at $9,388,124 in the last three months. 0.49% of the stock is owned by insiders.
Several analysts recently weighed in on the company. Zacks Investment Research raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $310.00 price target for the company in a report on Tuesday, April 9th. Robert W. Baird lifted their price objective on Thermo Fisher Scientific from $264.00 to $270.00 and gave the company an “outperform” rating in a report on Wednesday, January 30th. BTIG Research lifted their price objective on Thermo Fisher Scientific to $310.00 and gave the company a “buy” rating in a report on Tuesday, March 26th. Deutsche Bank lifted their price objective on Thermo Fisher Scientific from $275.00 to $300.00 and gave the company a “buy” rating in a report on Friday, March 22nd. Finally, Needham & Company LLC started coverage on Thermo Fisher Scientific in a report on Wednesday, January 2nd. They issued a “strong-buy” rating and a $271.00 price objective for the company. Two research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $293.33.
WARNING: This piece was originally reported by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.baseballdailydigest.com/news/2019/04/26/atwood-palmer-inc-sells-1050-shares-of-thermo-fisher-scientific-inc-tmo.html.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.
Featured Article: Buyback
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.